ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 33,481 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $59.39 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -107.98 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company’s 50 day simple moving average is $58.32 and its 200 day simple moving average is $60.76.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same quarter last year, the company posted $1.05 EPS. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $65,000. Ridgewood Investments LLC acquired a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $85,000. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals during the first quarter worth $106,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after buying an additional 579 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $207,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the topic of several research reports. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Raymond James increased their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.